drug
(hyaluronidase (recombinant, human) + immune globulin (human))
Marketedupdated 6mo agoby Baxalta Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (hyaluronidase (recombinant, human) + immune globulin (human))
- phase3A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
- phase3A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- phase1A Study of TAK-881 and HyQvia in Healthy Adults
- phase3Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
- phase1A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants
- phase3Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
- phase3A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
News(1)
- Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune diseaseBig Pharma-backed Nuvig Therapeutics has halted one of the two trials for its sole clinical asset after determining the program wouldn’t be able to advance quickly enough.fiercebiotech · 20d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that